Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NETTER-1: Lutathera in Midgut Carcinoid Tumours
NCT01578239Phase 3Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Sep 2012
- Primary completion
- Jul 2015
- Modality
- Peptides, Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of lutetium Lu 177 dotatate in midgut neuroendocrine tumor (MNET) (2 arms), sponsored by Advanced Accelerator Applications. Primary endpoint: Progression Free Survival at 34 months. Started Sep 2012; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
midgut neuroendocrine tumor (MNET)
Beyond the preview
Go deeper on NCT01578239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578239.